Regulus Therapeutics Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022
Period Ending	Jun '25 Jun 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022
Net Income	54.63	80.25	58.09	32.73
Depreciation & Amortization	140.05	95.19	44.33	36.43
Other Amortization	1.19	0.71	0.4	0.4
Loss (Gain) From Sale of Assets	0.17	0.8	1.17	0.05
Stock-Based Compensation	8.83	0.99	0.09	0.49
Provision & Write-off of Bad Debts	1.19	0.64	0.31	0.51
Other Operating Activities	45.54	1.07	2.51	0.34
Change in Accounts Receivable	-15.49	-15.49	-16.89	-13.78
Change in Inventory	25.12	21.92	-6.63	9.27
Change in Accounts Payable	1.6	-4.29	-0.52	-2.41
Change in Unearned Revenue	0.32	2.4	-	-
Change in Other Net Operating Assets	-9.2	-4.81	-1	2.54
Operating Cash Flow	253.94	179.38	81.86	66.56
Operating Cash Flow Growth	178.20%	119.13%	22.98%	-
Capital Expenditures	-126.63	-90.49	-43.51	-106.96
Sale of Property, Plant & Equipment	0.41	0.17	0.84	0.03
Cash Acquisitions	-7	-3.91	-	-
Sale (Purchase) of Intangibles	-0.29	-0.19	-	-
Investing Cash Flow	-133.52	-94.43	-42.67	-106.93
Long-Term Debt Issued	-	463.15	188.36	188.12
Long-Term Debt Repaid	-	-306.27	-175.05	-110.75
Net Debt Issued (Repaid)	-327.08	156.89	13.31	77.37
Common Dividends Paid	-220.86	-230.51	-52.5	-37
Other Financing Activities	-30.06	-6.71	-	-
Financing Cash Flow	-116.19	-80.34	-39.19	40.37
Net Cash Flow	4.23	4.62	-	-
Free Cash Flow	127.31	88.89	38.35	-40.4
Free Cash Flow Growth	173.47%	131.80%	-	-
Free Cash Flow Margin	16.73%	16.61%	15.76%	-27.18%
Free Cash Flow Per Share	7.03	11.53	7.52	-
Cash Interest Paid	28.78	28.78	18.9	8.67
Levered Free Cash Flow	106.13	-84.81	17.44	-
Unlevered Free Cash Flow	126.1	-65.31	28.89	-
Change in Net Working Capital	-16.22	145.05	21.7	-

Updated Aug 5, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q